FIELD: medicine.
SUBSTANCE: present invention provides a combination comprising at least oncolytic virus and one or more immunological control point modulators for use in treating a proliferative disease, such as cancer. It also refers to a kit containing said oncolytic virus and said one or more immunological control point modulators in separate containers. It also refers to a pharmaceutical composition containing an effective amount of said oncolytic virus and said one or more immunological control point modulators.
EFFECT: disclosed is a combination of oncolytic virus with modulators of immunological control points.
21 cl, 7 dwg, 1 tbl
Title |
Year |
Author |
Number |
ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION |
2015 |
- Silvestr Natali
- Gejst Mishel
- Rittner Karola
- Marshan Zhan-Batist
- Tiudelle Kristin
|
RU2696312C2 |
ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH |
2016 |
- Siurala, Mikko
- Liikanen, Ilkka
- Tahtinen, Siri
- Parviainen, Suvi
- Hemminki, Akseli
|
RU2725799C2 |
M2-DEFECTIVE POXVIRUS |
2019 |
- Klyajnpeter, Patritsia
- Marshan, Zhan-Batist
- Remi, Kristell
- Shmitt, Doris
|
RU2819245C2 |
POXVIRAL ONCOLYTIC VECTORS |
2008 |
- Ehrbs Filipp
- Folopp Zhoann
|
RU2508401C2 |
POXVIRAL ONCOLYTIC VECTORS |
2008 |
- Ehrbs Filipp
- Folopp Zhoann
|
RU2503717C2 |
DRUG FOR TREATING CANCER, COMBINATION DRUG, DRUG COMPOSITION, IMMUNOREACTIVE CELL, NUCLEIC ACID DELIVERY VEHICLE AND PRODUCT |
2020 |
- Tamada Koji
- Sakoda Yukimi
- Adachi Keishi
|
RU2833301C1 |
POX VIRAL ONCOLYTIC VECTORS |
2008 |
- Ehrbs Filipp
- Folopp Zhoann
|
RU2557312C2 |
IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT |
2019 |
|
RU2794261C2 |
ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE |
2018 |
|
RU2777523C2 |
ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR |
2018 |
|
RU2740713C1 |